Majzner_Lab
@Majzner_Lab
Followers
2,797
Following
1,279
Media
14
Statuses
363
Robbie Majzner's Lab at Dana Farber. Focus on CAR T cell signaling & engineering, cancer immunotherapy & ganglioside biology. Interested in curing kids!
Boston, MA but heart in 🇮🇱
Joined April 2021
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Venezuela
• 425460 Tweets
Canadá
• 333616 Tweets
#THEMUSICDAY
• 133244 Tweets
期日前投票
• 129580 Tweets
hoshi
• 91692 Tweets
Vinotinto
• 70555 Tweets
Rondón
• 51159 Tweets
選挙妨害
• 48979 Tweets
Angel Reese
• 47441 Tweets
ボボステ
• 47098 Tweets
リンツのチョコ
• 41552 Tweets
#黄金のワンスプーン
• 28263 Tweets
#キントレ
• 27647 Tweets
BELLE ON ITS SHOWTIME
• 24982 Tweets
ウルトラマンアーク
• 22977 Tweets
ボーボボ
• 22110 Tweets
श्यामा प्रसाद मुखर्जी
• 19983 Tweets
Manny
• 18211 Tweets
ソフトン
• 17737 Tweets
蓮舫赤軍
• 16276 Tweets
GULF LIVE IN JAPAN
• 16240 Tweets
Romo
• 15653 Tweets
ところ天の助
• 14101 Tweets
首領パッチ
• 13795 Tweets
Aramburu
• 12203 Tweets
リンドール
• 10978 Tweets
運転見合わせ
• 10930 Tweets
エンティーム
• 10749 Tweets
運転再開
• 10378 Tweets
Yangel
• 10304 Tweets
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy.
25
86
344
@BMWK
Thank you for your moral clarity, your support of Israel and hope for a future of peace. My holocaust survivor grandparents would be very touched by your words.
37
12
318
Our experience w/GD2 CAR T cells in 4 patients with DIPG/DMG was published today. This work taught us much about how to safely & effectively treat this disease w/CARs. Deeply grateful to patients & families who bravely trusted us as we learned together.
1/
9
92
301
Excited to share that
@Majzner_Lab
is moving to
@DanaFarber
@DFBC_PedCare
as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!
42
27
309
My lab at Stanford is hiring. We work on engineering new cancer immunotherapies and understanding their activity in early phase trials. Open postdoc positions as well as a technician with animal experience. Contact me if interested! Please retweet!
8
132
209
Thank you
@NatureMedicine
for your recognition of the growing lab! Excited for the new therapies we will bring to children with cancer in the next few years.
11 trailblazing early-career researchers, shaping the future of
#medicine
, share what they are most excited about right now and where their research is going in the next 5 years - read now:
10
57
255
9
8
184
Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo!
2
36
183
Happy to share our lab's first manuscript. In work led by
@JTheruvath_MD
, we tested a combo of FDA approved anti-GD2 with blockade of CD47, a macrophage checkpoint. Blocking CD47 unleashes patients' macrophages to phagocytose or 'eat' cancer cells. Combo was highly effective! 1/
📢 New in
@NatureMedicine
! Great work led by
@Majzner_Lab
@JTheruvath_MD
shows that the combo of anti-GD2 + CD47 blockade ⬆️ anti-tumor activity in 🐭 models of
#neuroblastoma
,
#osteosarcoma
&
#lungcancer
by modulating
#macrophage
activity
#immunotherapy
2
15
62
9
37
136
Happy to be a part of NexTGen team to solve the challenge of solid tumors in children. Cell therapies can get us there! Led by Martin Pule & Cath Bollard, grant will support 5yr research incl. 3 trials of CAR T in kids!
2
5
93
Final version of the paper is up… …much more to come at AACR next week…
Our experience w/GD2 CAR T cells in 4 patients with DIPG/DMG was published today. This work taught us much about how to safely & effectively treat this disease w/CARs. Deeply grateful to patients & families who bravely trusted us as we learned together.
1/
9
92
301
0
7
73
@ProfKFranke
This is a pathetic take on a horrible massacre. Your academic posturing reeks of moral cowardice - calling murder, torture, and rape "military action/response" - shameful!
@Columbia
- you are becoming more and more irrelevant to the lives of your alumni.
1
0
68
@MarcelaMaus
gave a fantastic talk about the different role of IFNg for CAR T cells for solid vs liquid tumors. Really cool and unexpected biology. Congrats
@SRBailey32
and Rebecca Larson!
1
6
65
Looking to hire a lab manager/technician for the new lab at Dana Farber. Please apply to join our group focused on engineering new cell therapies, especially for pediatric cancer. Job description is flexible - experience with mice and T cells preferred.
2
26
64
Happy to post about a great collaboration with
@KStegmaier_DFCI
led by
@Nathaniel_Mabe
and Min Huang
@StanfordPeds
where we identify GD2 loss and downregulation as a major resistance mechanism to anti-GD2 antibodies in neuroblastoma
3
10
60
Huge milestone-functional cure for many w/sickle cell& b-thal. Lots of focus on rapid clinical dev of CRISPR, but equal emphasis should be placed on discoveries by Stuart Orkin &
@bloodgenes
in hemoglobin biology/regulation. So important to fund basic science- FUELS translation!
In a major milestone for science, for medicine, and for patients, the world’s first CRISPR drug has been approved in the UK.
“A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory
24
344
2K
1
8
59
Thanks for featuring our story!
On this week's episode: A new LINK 🔗 CAR system from Dr. Robbie Majzner's group (
@Majzner_Lab
) can improve efficacy and prevent on-target, off-tumor toxicity of
#CART
cells.
📄
@Nature
:
🎧:
0
2
19
0
3
56
We are hiring a lab manager/tech for the new lab at DFCI! Please apply or get in touch if interested! The job will be part management and part science - very flexible -
0
7
49
Congratulation to Mari on her fellowship from AACR! My first post-doc making me proud!
Congratulations to Maria Caterina Rotiroti, PhD, the recipient of the 2022 AACR-Amgen Fellowship in Clinical/Translational Cancer Research. We look forward to her progress in engineering CAR T cells.
1
1
17
3
0
49
What an amazing pipeline and story here. Neoantigens from driver mutations that are shared between patients and can be targeted with patient derived TCRs.
@KlebanoffLab
- can’t wait to see more of these!
A high-throughput platform to find rare
#Tcells
that recognize shared cancer
#neoantigens
identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene
@KlebanoffLab
@MSKCancerCenter
@parkerici
4
69
217
0
5
46
It’s really unbelievable how modern science & technology is changing the course of incurable childhood diseases. Generations of pediatric residents remember caring for sick teenagers with CF in hospital - something that is now becoming rare. Will be true of sickle cell soon too.
This is Gunnar and his son Kaspar. Gunnar turned 32 today. At Kaspar's age a CF patient was expected to live into their early 20's. Gunnar is our hero and Kaspar is our miracle. To all who have shared this journey with
@cysticfibrosis
I cant say thank you enough. 🙏🏻😍
158
148
5K
0
2
39
A wonderful story about a fantastic mentor and trailblazer in the immunotherapy field
@cm35c
@MackallLab
Crystal Mackall, MD, is the first in our series of CAR-Trailblazer profiles spotlighting women pioneers in the field of cancer
#celltherapy
Read the full interview:
#CARTcell
@cm35c
@Majzner_Lab
@StanfordMed
@theNCI
@Stanford_CCT
0
0
10
0
5
38
Thank you
@CD_AACR
for featuring our story!
Read this week's Cancer Discovery
#ResearchWatch
:
Logic-Gated CARTCells Enhance Survival and Reduce On-Target Toxicity, a summary of the paper by Aidan Tousley,
@Majzner_Lab
et al.
@Stanford
0
2
8
0
3
38
Thanks to Erin Digitale
@StanfordMed
for explaining our story in a unique and accessible way!
0
3
35
Thank you SKC and partners for coming together and funding this research! It’s inspiring to see how driven families are in the fight against neuroblastoma.
We are thrilled to announce our funding of the Optimizing Immunotherapy for Refractory Neuroblastoma study along with partners
@zoe44life
,
@Ruperts_Revenge
,
@Wee_Oscar
,
@merrynlacy
and
@J_A_C_K999
3
7
22
0
3
34
Congratulations to my mentor Crystal Mackall
@MackallLab
@cm35c
who has always instilled in her trainees the importance of taking bold steps for the good of children with cancer!
Join us from 9:05-9:55 a.m. EST for the Richard V. Smalley Memorial Award and Lectureship. Hear from Dr. Crystal Mackall as she presents "CAR-T Cells for Solid Tumors: Charting a Path Forward."
#SITC21
1
2
13
0
2
33
I wrote a short perspective here about the implications of this important work that accompanies this article in
@GoHealio
by
@drewamorosi
1
6
27
this seems more impactful than any of the other allo. allo CAR vs new target (CD70) in a dz indication without an approved auto CAR. CR rate 20% so still room to improve, but its something! who knows about durability/persist, but at least they did B2M-KO. CD70 is on many cancers
THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES $CRSP
47% ORR in n=15 R/R TCL
0
3
13
2
0
27
Louai is one of the best cell engineers I've encountered. This system sets a new standard for safety and efficacy in regulatable CAR T cells.
Thrilled to announce that our SNIP paper is live
@CellCellPress
! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway
@StanfordMed
.
#CART
#Immunotherapy
#SynBio
#Cancer
.
1/
15
44
211
0
2
25
Saw
@Marcelamaus
present this at
#AACR2022
- really beautiful story! congrats.
Online at
@nature
: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by
@MarcelaMaus
and colleagues
3
92
305
0
2
23
Really great
This was a fun one.
@ebmrheum
offered to come on the show and grill me. I think it was a fun dialogue. Agreement and disagreement. Sort of dialogue that used to happen at universities.
9
11
109
0
1
22
@ProfKFranke
Pathetic! 10/7 was terrorism, not military response-hamas targeted children, raped women. Congrats for using academic position to whitewash terror w/verbal gymnastics. No matter your politics, u could be condemn evil. Instead u shame
@Columbia
. Hard to associate w/my alma mater!
1
0
22
We focused on building this as a Boolean logic AND-gate. Through iterative engineering, we generated LINK CAR, a system in which activation is dependent on 2 distinct antigens while there is no activation when just one is ligated. Not trivial – took ~2yrs and 100s of constructs!
2
4
22
The big step came from studying T cell signaling. Thanks to an incredible library of literature that was constructed by Art Weiss, Larry Samelson, Gary Koretzky & others, as well as a 3 min youtube video ()😀, we understood that the role of ZAP-70 is to...
1
1
19
phosphorylate LAT & SLP-76 which then form a scaffold for PLCγ. Because could initiate T cell signaling with ZAP-70 or PLCγ CARs, we hypothesized that we could also activate T cell by clustering both LAT and SLP-76 CARs (which are otherwise inactive). Amazingly it worked!
3
1
20
What an accomplishment to run a ~50,000 subject adaptive randomized trial while at the front lines of caring for pt w/COVID in 2020. The epitome of leadership in medicine and science. Thank you to the RECOVERY team!
The RECOVERY trial helped save >1 million lives
Here, we reflect on what it felt like to see results for the first treatment.
But most remarkable are the comments from frontline NHS staff & patients. Without them none of this would’ve been possible.
8
51
174
0
0
17
Thanks
@beckypferdehirt
for featuring our work!!! was fun to record this together.
New
@a16zBioHealth
Bio Eats World Journal Club episode is out! I had a wonderful time discussing the
@Majzner_Lab
's new work engineering CAR T cells with true boolean logic gates for improved safety and efficacy. Thanks to Robbie for joining. Listen in! 🎧
0
7
34
0
1
16
This model is so important for the field as we test new engineering methods to ensure CAR T cell safety.
@Majzner_Lab
is already using it!
We developed an improved on-target off-tumor toxicity model using a ROR1-targeting CAR with a 28 costim. We built an NFKB activation reporter using
@michaelzlin
's Antares and demonstrated that ROR1(F).28z CAR-T cells attack healthy ROR1 expressing cells in the lung.
7/
1
1
11
0
0
17
We asked whether we could initiate T cell signaling downstream of the TCR complex and created CARs consisting of endodomains from cytosolic proximal signaling molecules rather than traditional costim and CD3ζ. Much to our surprise, some of these Frankenstein molecules worked!
1
2
17
The tumor regressions & clinical improvement were beyond anything we expected on this 1st dose level of a Phase 1 trial for an incurable disease. Thankful to mentors/leaders
@michelle_monje
(PI) and
@cm35c
(IND holder) and co-first author
@SRamakrishna_MD
(correlative leader) 2/
2
3
16
Routing cancer cells to the right path may boost treatment
0
0
17
We hope this represents a watershed moment where we start to turn the tide against this dreadful disease & other incurable childhood cancers. This is truly a story of the power of the peds oncology community (researchers & families). I’d like to mention a few in particular. 4/
1
2
15
Many people to thank for helping with this work. Aidan did all heavy lifting & despite not having any formal training in science, he built what will hopefully be a transformative system. Shows what hard work & imagination can accomplish! He will be a star MD/PhD student & doctor.
1
1
16
CARs have revolutionized the care of heme cancers & are starting to show promise in solid tumors. But since they were invented ~30 yrs ago, they have looked similar, linking an antigen binder outside the cell to CD3ζ, master switch of T cell signaling, inside the cell (+costim).
1
1
16
GD2 is a cancer target identified in 80’s. Immunotherapy leaders Ralph Reisfeld, Alice Yu, Paul Sondel & NK Cheung pioneered anti-GD2 to treat children w/neuroblastoma. Reisfeld's life as a Jewish refugee who escaped Nazi Germany resonates strongly w/me!
5/
1
3
16
@JanakiramMurali
@SandyWong02111
Cd19 loss & downregulation are pretty common after cd19 CAR &
1
2
15
What a shame. Whether you agree with him on everything, something, or nothing,
@VPrasadMDMPH
is thoughtful & engaging. Why do academics think shutting down voices is the way to advance science & knowledge? Listen & debate! This is pretty feeble -why are we afraid of disagreement
The ACCP Board of Regents has provided an update regarding the choice for the 2023 ACCP Annual Meeting Keynote Address. Please read the update here:
77
29
326
2
0
15
Looking forward to working with
@straathof_karin
@squezadd
@thisiscryc
@CruzLabMimetic
@kevlitchfield
@EmmanuelDonnad1
@DrPHanley
@yarmo111
and many others especially our amazing parent advocate team members
@AlicesArc
@evan_foundation
@KFILE
1
5
14
@JacobPlieth
If B cells return quickly and CAR persistence is not necessary, I suspect that the cd20 or cd19 x cd3 bispecific engagers are going to be very active in autoimmunity. It’s interesting that this hasn’t been tried yet…
2
2
15
come work with us!
Please RT: faculty position at Stanford! PhD, MD, MD/PhD candidates in the broadly-defined fields of pediatric cancer or stem cell transplant, laboratory and/or computational research programs welcome. Amazing environment! Feel free to contact me + check:
1
97
111
0
2
14
2nd author Mari was there to lend expertise and help throughout. Proud that all members of our lab contributed. Also thanks to
@molecular_elena
(all things WB!)
@CalebLareau
@Satpathology
@LouaiLabanieh
@MackallLab
@EvanWeberPhD
@Guiller41577298
@Dunn_Lab
and twitterless collabs.
1
1
14
We are recruiting a pediatric oncologist to join our growing cell therapy team to work together to bring innovative therapies to kids! Link below
We are looking for a doc excited about CAR-Ts to join our booming cell therapy team! Join us! 🧬🥼
0
26
91
0
3
14
Without tissue donations from families, would never have known GD2 is on DIPG. Without tremendous efforts for anti-GD2 in neuroblastoma, would not have pursued GD2 as a target. Without Baylor showing that GD2 CAR T cells could be safe, trial may not have been pursued at all! 9/
1
3
13
The Baylor group tested GD2 CAR despite potential for tox due to GD2 expression on normal nerves. They proved that this could be done safely & effectively. We now understand that our GD2 CAR T cells don’t attack nerves because they express much lower levels of GD2 than tumors. 7/
1
4
13
Compared to CD3ζ CARs, ZAP-70 CARs were much more effective in models of pediatric cancer. Enhanced activity was driven by increased expansion and persistence and even protected mice from tumor rechallenge. We are still working to understand the mechanism for improved activity.
1
1
14
This is truly a story of the success of pediatric oncology and what can be achieved when families and scientists work together and build on one another’s discoveries. This is also a story about the potential power of CAR T cells for pediatric cancer. 10/
1
2
13
CARs containing portions of ZAP-70 or PLCγ, important propagators of signal transduction within the T cell, demonstrated in vitro activity similar to traditional CD3ζ CARs. We also noticed that ZAP-70 CARs appeared less exhausted after culture so decided to test them in mice.
1
1
13
Loved working w/
@mvicaracal
who was an excellent, responsive & efficient editor.
@TeamSciStories
provided beautiful artwork. Thank you to the
@NIHDirector
&
@parkerici
for support! Our lab is hiring @ all levels (postdocs, techs, scientists) so please get in touch if interested.
0
0
13
So many people involved, especially our cell therapy team, master clinicians who cared for these patients with all their hearts.
@LioraSchultz
@karaldavis
@SRamakrishna_MD
@BeckyRichardsMD
@vbarsan
@cm35c
@michelle_monje
@campen_cynthia
Sonia Partap, Jasia Madhi & Jen Moon 13/
1
3
12
Thank you
@TeamJJTueb
@Philip___Bucher
for your insights!
Judith Feucht and
@Philip___Bucher
from
@CoE_iFIT
giving their view on
@Majzner_Lab
´s impressive article "Co-opting signalling molecules enables logic-gated control of CAR T cells"().🧬
Published now in
@NatureCancer
1
18
53
0
0
12
Drug development for orphan diseases is notoriously difficult and expensive, and thus childhood cancer usually gets ignored. Cell therapy can change that because these therapies can be discovered, designed, and tested in academic laboratories and hospitals. 11/
1
3
11
Years later, w/tumors donated by families after children died of DIPG, Chris Mount,
@michelle_monje
discovered GD2 highly expressed. W/
@cm35c
, we found GD2 CAR T cells were effective in mice. Natural next step to bring this fwd through
@Stanford_CCT
8/
1
3
11
Fast fwd many years to Malcolm Brenner’s group at Baylor incl. Claudia Rossig & Martin Pule who developed & translated the 1st GD2 CAR T cell to children with neuroblastoma. This group was innovative and bold, setting the stage for cell therapy in kids!
6/
1
3
11
With organizations such as
@parkerici
@CureSearch
@AlexsLemonade
@CIRMnews
@StBaldricks
@theNCI
, who supported both the basic research & clinical trial, peds oncologists can bring cutting edge technology and novel therapies to children w/out depending on pharma. 12/
1
3
11
We hope LINK will enlarge the universe of antigens that can be safely targeted with CARs, unleashing them against solid tumors & diseases such as autoimmunity & fibrosis. Also, we show that the cell's intracellular machinery can be repurposed into synthetic surface receptors.
1
1
11
As presented recently by
@cm35c
&
@michelle_monje
, the story continues to evolve as we apply the lessons from these 1st patients to more effectively treat additional children & young adults with this universally fatal disease. Looking fwd to sharing more in months to come.
3/
1
2
11
@parkerici
@CD_AACR
Thanks for highlighting - tagging
@mileslinde
and
@RaviMajetiMD
@majetilab
who did the work!
0
0
9
Thanking many contributors, including those on twitter
@BitaSahaf
,
@AnnaGeraghty2
@AgnesReschke
@EstherHNie
@GerryGr96914055
@Katheri32070689
@shabnumpatel
@cbaggott6
@snehitp
@GoodZinaida
@Shawn_M_Gill
@missingboy87
@FilbinMariella
@StanfordPeds
@Stanford_Neuro
@StanfordCancer
0
4
10
@TeamSciStories
Thank you
@TeamSciStories
for beautifully helping us tell our story! At a recent talk I gave, someone commented on the beautiful figures and color scheme - of course I had to tell them we could take none of the credit. I highly recommend working with your team!
2
0
10
Pathetic! 10/7 was terrorism, not military response-hamas targeted children, raped women. Congrats for using academic position to whitewash terror w/verbal gymnastics. No matter your politics, u could be condemn evil. Instead u shame
@Columbia
. Hard to associate w/my alma mater!
Columbia/Barnard faculty have signed an open letter supporting our students, making the point that identifying with the suffering of Gazans and historically contextualizing the current war in Israel/Gaza is not anti-Semitic. Please read and share.
4K
3K
10K
0
0
10
@OdedRechavi
@OdedRechavi
thanks for making us laugh during this awful time. Your posts are the only ones that make me smile & laugh during incessant doom-scrolling. I’m sure I’m not the only Jewish scientist who feels the same! Praying for your continued safety & that of our whole nation.
0
0
10
I should add we are also looking for a scientist/senior scientist so anyone with more experience, especially in adoptive cell therapy/immunology, please let me know!
My lab at Stanford is hiring. We work on engineering new cancer immunotherapies and understanding their activity in early phase trials. Open postdoc positions as well as a technician with animal experience. Contact me if interested! Please retweet!
8
132
209
0
4
9
@JReinerMD
Pathetic academic word salad. They will be remembered for excusing moral depravity and murder.
2
1
10
@MaxMamonkin
Congratulations Max! Glad to see the use of dasatinib in manufacturing is being used - doing the same (no ibrutinib) in our gd2 car trials.
@EvanWeberPhD
1
0
9
@bloodgenes
congratulations - a beautiful example how a fundamental scientific discovery can lead to a huge therapeutic advance!
0
0
8
We tested LINK in a mouse model of on-target, off-tumor toxicity w/a ROR1 CAR that recognizes ROR1 on mouse lungs, resulting in toxicity. While CD3ζ CARs or other AND-gates resulted in death of the treated mice, those treated with LINK suffered no tox & tumors were eradicated.
2
1
11
Congratulations to Francesca Del Bufalo
@RTheR2
, Concetta Quintarelli, Franco Locatelli and team!
1
0
9
Go Sabine!
Beyond excited to start this new adventure as an Assistant Professor at
@StanfordMed
. As part of
@StanfordPeds
,
@StanfordCancer
and
@Stanford_CCT
my lab's mission is to engineer cellular immunotherapies against novel, promising target antigens on childhood cancer. Let's go!
12
10
144
0
0
9
@EvanWeberPhD
@CHOP_Research
@PennMedicine
Two comments:
1-CONGRATULATIONS! So great!
2-Are you interested in making my lab's website :)
2
0
8
Thanks
@CancerGrand
@TheMarkFdn
@CR_UK
@theNCI
for support. Congrats to Stanford NexTGen colleagues
@Satpathology
@CarolynBertozzi
& Irv Weissman as well as other Stanford CGC teams Paul Mischel
@HowardYChang
@michelle_monje
Calvin Kuo
@Prof_Lundberg
1
0
8
@bloodgenes
As a pediatrician and scientist, it's inspiring to see science fueling the transformation of care for children with incurable diseases-
@VertexPharma
at the center of such meaningful advances for patients with cystic fibrosis and now hemoglobinopathies!
1
0
9
@OrentasR
@EvanWeberPhD
@MackallLab
I was once excited about a CAR I engineered in
@MackallLab
- IL2 secretion in response 2 tumor was off the charts. But it was a dud in vivo. Went back in vitro, very high exhaustion markers & lots of baseline IFNg. Lack of tonic signaling also essential - thanks
@ahartlong
!
1
0
5
Thanks 2 many collaborators incl those on twitter
@Satpathology
@mileslinde
@majetilab
@CarolynBertozzi
@smithbenjie
#glycotime
@michelle_monje
@AnnaGeraghty2
@marius_mader
@WernigLab
, members of my lab incl.
@Guiller41577298
, and to funders
@theNCI
@AlexsLemonade
@TheVFoundation
1
0
7
@skjask
What a joke - he claims that modern hebrew destroyed local Jewish languages like Yiddish -it was the Nazis that killed our Yiddish speaking families and destroyed the language. An antisemite trying to dictate our choice of language - it’s clear who is the true colonialist…
0
0
6
Sorry - if interested, send me an email. Email address on my Stanford profile.
2
4
7
@JTheruvath_MD
Anti-GD2 is routinely used to treat kids with neuroblastoma but ~50% of patients still relapse. Also, although GD2 is expressed on osteosarcoma, anti-GD2 has not been effective in that disease. We think the combination with anti-CD47 can change that. 3/
1
1
6
@VPrasadMDMPH
honest Q
@VPrasadMDMPH
@AaronGoodman33
-what would U do if pt w/relapsed ALL post HSCT, now in remission post-CD19 CAR w/long term B cell aplasia & no symptoms (yet...). I would err on side of caution.
@AaronGoodman33
aren't your pt HSCT? dift than Epic SR-no data but reasonable?
2
0
5
For background - this is the target of CRISPR in the product which enabled the functional cure of these horrible diseases!
0
0
7
@OdedRechavi
I would love to host Israeli postdocs here
@Majzner_Lab
@DanaFarber
! Leadership is very supportive and speaks with moral clarity.
0
0
6
i think i saw a poster once that their B2M efficiency was ~50%. i assume the same for CD70 KO. and they select only CD3 negative pre-infusion. will be very cool to see which cells from a heterogenous pot persist. hopefully they have strong correlatives planned!
3
0
5
@CalebLareau
@Nature
@Satpathology
Congratulations Caleb and Ansu! What a creative way to utilize genomic data that most others would ignore! looking forward to lots more of this unique work from the newly minted
@CalebLareau
lab &
@Satpathology
0
0
6
@Prof_Oak_
My take: if T cell persistence/long term B cell aplasia isn’t required (“immunological reset”), blincyto & cd20xcd3’s may work here. Not sure why haven’t heard from Amgen in this space. I’m a huge CAR fan but if all u need for autoimmunity is 1 & done, cd3 engagers likely to work
1
0
5
An unbelievable speech that speaks up for all of global jewry of all backgrounds . Thank you
@mijalbitton
for saying it so clearly.
Our message to NYU and our communities is clear: we are strong, we are not afraid, we are outraged by supporters of terror and we join with good people everywhere to fight back!
275
877
4K
0
0
4
Great working with
@LisaHaas0107
and
@NatureCancer
- had a great experience with enthusiasm and strong support for authors! Thank you!
1
0
5
@pdhsu
And basic science!
Huge milestone-functional cure for many w/sickle cell& b-thal. Lots of focus on rapid clinical dev of CRISPR, but equal emphasis should be placed on discoveries by Stuart Orkin &
@bloodgenes
in hemoglobin biology/regulation. So important to fund basic science- FUELS translation!
1
8
59
1
0
5
@JTheruvath_MD
Thanks to support from
@NCICTEP_ClinRes
& CRADA w/
@GileadSciences
(formerly CD47 Inc.), we are proud to test this approach in kids across US/Canada. Peds-CITN-03 is the 1st trial to test anti-CD47 in children and 1st trial of anti-GD2/anti-CD47 in humans
1
1
4
@AaronGoodman33
@DocsDock200
That’s quite a take-secondary malignancies occur after haplo as well plus the risk of GVHD! Curative auto w/gene therapy is new (not even approved) & risks will be uncovered but initial data looks great. Allo has many potential bad outcomes. My $ is on auto/gene therapy long term
0
0
3
@JTheruvath_MD
@NCICTEP_ClinRes
@GileadSciences
Many people involved in this work at Stanford and elsewhere. Tagging those on twitter. Special shout out to
@smithbenjie
and
@CarolynBertozzi
for help in all things glyco! And thanks to Crystal Mackall
@MackallLab
for the mentorship always!
2
2
4